Healthy Skepticism Library item: 10799

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

Lehman S.
Abbott, Brazil Agree on AIDS Drug Cost
Associated Press 2007 Jul 4
http://biz.yahoo.com/ap/070704/brazil_aids_drug.html?.v=1

Full text:

Abbott Laboratories and Brazil Reach Agreement on Cost of AIDS Drug

SAO PAULO, Brazil (AP) — The Brazilian government and Abbott Laboratories have agreed to reduce the price of an anti-AIDS drug by nearly 30 percent this year, and even more next year, the Health Ministry and the company said.

Wednesday’s agreement with the U.S.-based company lowers the price of each Kaletra pill to US$0.73 (euro0.54) from US$1.04 (euro0.76) until the end of the year. In 2008, each pill will cost US$0.68 (euro0.50), or “US$1,000 (euro734) per patient per year,” the Health Ministry said.

Kaletra, a protease inhibitor, is one of the most commonly used anti-AIDS drugs in Brazil, which provides free AIDS drugs to anyone who needs them. Brazil manufactures generic versions of several drugs that were in production before the country enacted an intellectual property law in 1997 to join the World Trade Organization

In a pricing dispute over another AIDS drug, Brazil in May bypassed the patent on Edaviren held by U.S. drug manufacturer Merck & Co. to manufacture or buy generic versions.

In that case, President Luiz Inacio Lula da Silva issued a “compulsory license,” a legal mechanism that allows a country to manufacture or buy generic versions of patented drugs while paying the patent holder only a small royalty.

The Brazilian government rejected Merck’s offer to sell the drug at a 30 percent discount — for US$1.10 (euro0.81) per pill, down from US$1.57 (euro1.15).

The country was seeking to purchase the drug at US$0.65 (euro.48) per pill, the same price Thailand pays.

Abbott previously said it would reduce the price of the drug in 45 “low and low-middle income countries,” such as Brazil.

“We wanted Brazil to benefit from the same price offered to other countries in the same level of economic development,” Heather Mason, Abbott’s vice president for Latin American and Canada, said Wednesday. “It makes it easier for the government of Brazil to provide medicine to a growing number of patients.”